Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC.

Community Practice Connections™: Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing Cardiovascular Disease & CV Risk

Access Activity

Overview / Abstract:

Target Audience

This educational program is directed toward all attendees of the 2021 ASCP Internal Medicine Meeting. We invite primary care physicians, diabetologists, endocrinologists, cardiologists, certified diabetes educators, nurse practitioners, physician assistants, and other health care providers who treat patients with T2D to participate in the online enduring program.

Program Overview

Type 2 diabetes (T2D) and cardiovascular disease (CVD) share several risk factors as well as targeted treatment strategies. Although impaired glucose metabolism plays a central role in the pathology of CV complications in patients with T2D, several studies have demonstrated that CV risk cannot necessarily be reduced simply by achieving a therapeutic glucose goal. The focus on glucose control is shifting; it is expanding to include a comprehensive and ongoing assessment of patients’ CV risk.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the webcast Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes Regarding Cardiovascular Disease and CV Risk, held at the ASPC 2021 Internal Medicine meeting in July 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with T2D and CVD, putting recent trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

Review current treatment guidelines for the reduction of CVD risk in patients with T2D
Evaluate the real-world evidence for reducing CV events and hospitalization to improve outcomes for patients with T2D
Apply emerging clinical data on issues concerning the treatment and prevention of CVD in patients with T2D

Expiration

Aug 31, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5 AMA PRA Category 1 Credit(s)™

Accreditation

ACCME

Presenters / Authors / Faculty

Faculty

FACULTY_NAME
Peter P. Toth, MD, PhD, FCCP, FASPC, FAHA, FESC, FACC
President, American Society for Preventive Cardiology
Director, Preventative Cardiology
CGH Medical Center
Sterling, IL

FACULTY_NAME
Harold Edward Bays, MD, FOMA, FTOS, FACC, FNLA, FASPC
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

FACULTY_NAME
Pam R. Taub, MD, FACC, FASPC
Director, Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
Division of Cardiovascular Medicine
UC San Diego School of Medicine
La Jolla, CA

Sponsors / Supporters / Grant Providers

Boehringer Ingelheim and Eli Lilly.

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Type 2 Diabetes Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map